Cargando…
Safety and Humoral and Cellular Immunogenicity of the BNT162b2 SARS-CoV-2 Vaccine in Liver-Transplanted Adolescents Compared to Healthy Adolescents
Since BNT162b2 was approved to prevent COVID-19 in children, we aim to compare the safety and immunogenicity of the BNT162b2 vaccine in liver-transplanted (LT) and healthy adolescents. LT and healthy adolescents received two doses of 30 µg of BNT162b2. All were evaluated for total COVID-19 antibodie...
Autores principales: | Sintusek, Palittiya, Buranapraditkun, Supranee, Khunsri, Siriporn, Saengchaisukhonkit, Varattaya, Vichaiwattana, Preeyaporn, Srimuan, Donchida, Thongmee, Thanunrat, Poovorawan, Yong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9413008/ https://www.ncbi.nlm.nih.gov/pubmed/36016212 http://dx.doi.org/10.3390/vaccines10081324 |
Ejemplares similares
-
Safety and Efficacy of a Third Dose of the BNT162b2 Vaccine in Liver-Transplanted and Healthy Adolescents
por: Sintusek, Palittiya, et al.
Publicado: (2023) -
Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study
por: Wanlapakorn, Nasamon, et al.
Publicado: (2022) -
Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults
por: Yorsaeng, Ritthideach, et al.
Publicado: (2022) -
Safety and Immunogenicity of the Third Booster Dose with Inactivated, Viral Vector, and mRNA COVID-19 Vaccines in Fully Immunized Healthy Adults with Inactivated Vaccine
por: Kanokudom, Sitthichai, et al.
Publicado: (2022) -
The Fourth Dose of mRNA COVID-19 Vaccine Following 12 Different Three-Dose Regimens: Safety and Immunogenicity to Omicron BA.4/BA.5
por: Kanokudom, Sitthichai, et al.
Publicado: (2023)